Treatment Study for Patients with Prostate Cancer Undergoing Active Surveillance
This is a multicenter, randomized, open label exploratory study, conducted in the US and Canada, evaluating the efficacy and safety of enzalutamide for extension of time to prostate cancer progression (pathological or therapeutic) in patients with clinically localized, histologically proven prostate cancer that is categorized as low risk or intermediate risk and who are under active surveillance.
In order to participate you must meet the following criteria:
- Have histologically proven adenocarcinoma of the prostate diagnosed within 6 months of screening.
- Have the ability to swallow study drugs and to comply with study requirements throughout the study.
This is a partial list of elgibility requirements.